 Home > Biochemistry News > Biotechnology News > First-line treatment of gastroesophageal adenocarcinoma HER2 targeting bispecific antibody achieves 90.9% disease control rate

First-line treatment of gastroesophageal adenocarcinoma HER2 targeting bispecific antibody achieves 90.9% disease control rate

 Last Update: 2021-10-11
 Source: Internet
 Author: User

Tags

herpes 1 2

18 com

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Zymeworks announced that it is investigating zanidatamab, a bispecific antibody therapy targeting HER2, and has achieved positive results in a first-line clinical trial for the treatment of HER2-expressing gastroesophageal adenocarcinoma (GEA) patients
.
As of March 18, 2021, of the 22 patients that can be evaluated, zanidatamab was used in combination with standard chemotherapy to achieve a confirmed objective response rate of 68.

Zanidatamab is a bispecific antibody that can simultaneously bind to two non-overlapping epitopes of HER2
.
This unique design produces multiple mechanisms of action, including dual HER2 signal blockade, increased clearance of HER2 protein from the cell surface, and enhanced antibody-mediated cytotoxicity, resulting in encouraging anti-tumor activity in patients

▲Zanidatamab has a unique mechanism of action (picture source: reference [2])

Reference materials:

[1] Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress.

Retrieved September 12, 2021, from https:// news/home/20210912005060/en

[2] Zymeworks Corporate Presentation.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.